We identify and experimentally characterize CLK1 as a candidate oncogenic dependency in pediatric HGGs and propose that targeting of aberrant splicing and/or its resulting downstream proteins may offer additional therapeutic avenues for precision cancer therapy. The gene discussed is CLK1; the disease is cancer.